Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD1979 in Healthy Volunteers
NCT02072993Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in obesity comparing AZD1979 with Placebo (2 arms). Primary endpoint: Safety variables up to 62 days. Started Mar 2014; status: terminated.
02
Drugs
AZD1979
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02072993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072993.